Carl Zeiss Meditec AG has confirmed that Bronwyn Brophy O’Connor, currently CEO of the Vitrolife Group in Sweden, will assume the role of CEO on December 1, 2026. On the same date, she will join the Executive Board of Carl Zeiss AG with responsibility for the Medical Technology segment. Her appointment as successor to current CEO Andreas Pecher was first announced in May 2026. With the start date now confirmed, she will take over leadership from Andreas Pecher, who has served as interim CEO since January 1, 2026.
“I am delighted to join Carl Zeiss Meditec and the ZEISS Group. The company combines deep scientific expertise, close customer relationships and a strong commitment to improving patient care. I look forward to working with our teams and customers to build on these strengths, advance innovation and successfully shape the next stage of the company’s transformation,” said Bronwyn Brophy O’Connor.
Peter Kameritsch, Chairman of the Supervisory Board of Carl Zeiss Meditec AG, commented, “With Bronwyn Brophy O’Connor, Carl Zeiss Meditec is gaining an internationally experienced medtech executive who will bring a strong customer and innovation perspective to the company. We wish her a great start.” Dr. Michael Bolle, Chairman of the Supervisory Board of Carl Zeiss AG, added, “We would like to thank Andreas Pecher, both for his temporary dual role as CEO of the ZEISS Group and interim CEO of Carl Zeiss Meditec AG, and for providing important momentum during this period. With her excellent skills, Bronwyn Brophy O’Connor will now be able to further advance the strategy and transformation of the Medical Technology segment forward and contribute to the success of the ZEISS Group.”
Effective December 1, 2026, the Management Board of Carl Zeiss Meditec AG will comprise Bronwyn Brophy O’Connor as CEO and Justus Wehmer as CFO. The Executive Board of Carl Zeiss AG will comprise Andreas Pecher (President and CEO), Stefan Müller (CFO), Bronwyn Brophy O’Connor (Head of the ZEISS Medical Technology segment), Sven Hermann (Head of the ZEISS Consumer Markets segment), Dr. Frank Rohmund (Head of the ZEISS Semiconductor Manufacturing Technology segment), and Dr. Marc Wawerla (Head of the ZEISS Industrial Quality & Research segment).
Brophy O’Connor brings a wealth of experience to the role. She studied at Dublin City University in Ireland, earning a bachelor’s degree in International Marketing and Languages (Spanish and French) and an MBA in 2002. She began her career at Johnson & Johnson in 1997, serving in roles of increasing seniority and ending as General Manager of the Cardiovascular Care Group for the U.K. & Ireland in 2012. She then joined Covidien, which was later acquired by Medtronic. From 2013 until 2018, she served as Vice President Early Technologies EMEA and later as President Women’s Health at Medtronic in Boston, USA. In 2019, she joined Thermo Fisher Scientific as President for the EMEA region and one year later was promoted to Global President of the Immunodiagnostics Division in Uppsala, Sweden. Since 2023, she has been CEO of the Vitrolife Group, a global medtech company publicly listed on the NASDAQ Stockholm.
Carl Zeiss Meditec AG, listed on the TecDAX and SDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. With 5,784 employees worldwide, the Group generated revenue of EUR 2,228m in fiscal year 2024/25. The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad. For more information, visit www.zeiss.com/med. The original release is available on www.newmediawire.com.
